Vascular Biogenics Ltd (VBLT)

[gr8db8]

2017 - looking ahead

Every time I think about what's upcoming, I reflect back to the 1 slide that I saw presented at SNO regarding the company's VTS platform:

Anti angiogenesis
Pipeline Product / Promoter / Transgene / Gene Therapy Mechanism / Development stage
VB-111 / PPE-1-3X / Fas-c / Cell death induced by the Tumor itself / Phase 3
VB-311 / PPE-1-3X / TK / Inducible system. Cell death only upon supply of oral drug / Pre-clinical
VB-511 / PPE-1-3X / E1 / Conditional replication-efficient virus / Pre-clinical

Pro angiogenesis (Ischemia)
Pipeline Product / Promoter / Transgene / Gene Therapy Mechanism / Development stage
VB-211 / PPE-1-3X / VEGF/PDGF / Targeted delivery of growth factors / Pre-clinical
VB-411 / PPE-1-3X / Stabilized HIF1?/ Targeted expression of pro-angiogenic master regulator / Pre-clinical

In addition to the NASH candidates like VB-201 and VB-703.

Aside from VB-111, everything else is a long ways off but there are some very interesting developments ... especially VB-311 and the NASH candidates, imo. 2017 is a make-or-break year for the company. 2017 is when VB-111 will mature with data, which we all have been patiently waiting to see.

Still, I will be interested in the other pipeline products and see if they move ahead in their development. I am also interested in learning why the company needed the additional funding - how are they all are related? 2017 will be an interesting year!